Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ascendis Health's Debt-to-EBITDA or its related term are showing as below:
JSE:ASC's Debt-to-EBITDA is not ranked *
in the Medical Distribution industry.
Industry Median: 2.45 * Ranked among companies with meaningful Debt-to-EBITDA only.
Ascendis Health (JSE:ASC) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ascendis Health Debt-to-EBITDA Related Terms
Ascendis Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ascendis Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:ASC vs PHBI, GCAN, SGBI: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Ascendis Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Health Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ascendis Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ascendis Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.
Ascendis Health (JSE:ASC) has a Debt-to-EBITDA of -0.21 as of Jun. 2023. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ascendis Health.
Is Ascendis Health's Debt-to-EBITDA too high?
Ascendis Health's current Debt-to-EBITDA is -0.21. Overall, Ascendis Health has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Health's Debt-to-EBITDA compare to PHBI and GCAN?
Ascendis Health's Debt-to-EBITDA of -0.21 can be compared against companies in the Medical Distribution industry. The industry median Debt-to-EBITDA is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ascendis Health. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Health's current Debt-to-EBITDA is -0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Health stock overvalued right now?
Ascendis Health (JSE:ASC) has a current Debt-to-EBITDA of -0.21. The current Debt-to-EBITDA is -0.21. Ascendis Health's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ascendis Health (JSE:ASC), the current Debt-to-EBITDA is -0.21 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Health Ltd is a health and wellness investment holding Company that holds investments in a number of companies that market and distribute a portfolio of brands, products, and medical devices. The company operates in two segments: i) Consumer Health (wellness, health supplements, speciality ingredients and compounded medicines) and ii) Medical Devices (distributor of medical devices, in vitro diagnostic products and orthopaedic equipment). The company generates the majority of its revenue from the Medical Devices segment.
11GF Score
Get the complete analysis for JSE:ASC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:ASC has been successfully added to your 
